Verubecestat: Another one bites the dust?
Merck announced on Tuesday, February 14, that yet another clinical trial of a promising Alzheimer’s disease drug had failed. The trial was testing the safety and efficacy of verubecestat, an oral therapy that, at some doses, can reduce amyloid beta production by as much as 90% (Kennedy et al., Science 2016). more >
“What can we learn from the sleeping brain?”
The 23rd UCI Distinguished Lecture Series on Brain, Learning, and Memory hosted by UCI MIND, UCI Ayala School of Biological Sciences, and UCI Center for the Neurobiology of Learning and Memory was held on February 7, 2017, at the Irvine Barclay Theatre.
“Patients ‘relieved’ by amyloid scans”
February 8, 2017
Learn more about a recent research study conducted by UCI MIND Co-Director, Dr. Joshua Grill, and colleagues to better understand patient and caregiver reactions to clinical amyloid imaging.
Research Suggests Space Travel Affects the Brain
“This is not a deal-breaker,” co-author Charles Limoli, a neurobiologist at the University of California, Irvine, said last fall. “I do not think that during the course of a trip to Mars and back the astronauts will come back with anything remotely similar to full-blown Alzheimer’s. more >
Join us! Feb 7 Distinguished Lecture with Dr. Ruth Benca
Please join UCI MIND, UCI CNLM, and the Ayala School of Biological Sciences on February 7, 2017 @ 7:30 PM for the 23rd UC Irvine Distinguished Lecture Series on Brain, Learning and Memory. Dr. Ruth Benca, renowned sleep medicine expert and Professor and Chair for the Department of Psychiatry and Human Behavior, will present a lecture on “What can we learn from the sleeping brain?”
Sleep is a universal and fundamental process that is present in every animal species and occupies a third of our lives. more >
Solanezumab fails in Phase 3: What do we know?
December 6, 2016
Joshua Grill, PhD, and Aimee Pierce, MD
This week, at the Clinical Trials on Alzheimer’s Disease (CTAD) meeting in San Diego, we will likely learn more about the recent announcement from Eli Lilly and company that their Phase 3 clinical trial of the monoclonal antibody against the soluble form of beta amyloid, solanezumab, did not demonstrate adequate efficacy to pursue approval from the U.S. more >
UCI MIND featured on KCAL9/CBS2 2 nights in a row
December 1, 2016
UCI MIND on 60 Minutes
Did you hear UCI MIND researcher Dr. Claudia Kawas last night on 60 Minutes? Click here to read the script and learn more.
A December to Remember Gala Honoree Dr. Ira Lott
Ira T. Lott, M.D. is the Director of the UCI MIND Down Syndrome Program and Professor Emeritus of UC Irvine School of Medicine. While focused on helping people with Down syndrome, Dr. Lott is also expanding knowledge about Alzheimer’s disease in the general population. more >
A December to Remember Gala Honorees Burton & Linda Young
Linda and Burton have worked tirelessly to increase research funding for treatments and a cure for Alzheimer’s disease at UCI MIND. more >